One of the experimental mAbs provided nearly complete protection against lymphoma when tested in mice.

Thursday, October 27, 2022 Experimental monoclonal antibodies show promise against Epstein-Barr virus An electron microscopy image showing three Epstein-Barr virions. Credit: NIAID A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus blocked infection when tested in human cells in a laboratory setting. One of the experimental mAbs provided nearly complete protection against lymphoma when tested in mice. The results appear online today in the journal Immunity.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107